Acebutolol - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)Enzymes (1)Transporters (2)

Targets (2)Enzymes (1)Transporters (2)Biointeractions (5)

Identification

Name

Acebutolol

Accession Number

DB01193 (APRD00772)

Type

Small Molecule

Groups

Approved

Description

A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(±)-acebutolol

3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide

5'-butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone

Acebutololum

Acetobutolol

N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide

N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Acebutolol Hydrochloride	B025Y34C54	34381-68-5	KTUFKADDDORSSI-UHFFFAOYSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Acebutolol	Tablet	400 mg	Oral	Sanis Health Inc	2010-02-25	Not applicable	Canada
Acebutolol	Tablet	200 mg	Oral	Sanis Health Inc	2010-02-25	Not applicable	Canada
Acebutolol	Tablet	100 mg	Oral	Sanis Health Inc	2010-02-25	Not applicable	Canada
Acebutolol - 400 - Tab 400mg	Tablet	400 mg	Oral	Pro Doc Limitee	1996-12-31	Not applicable	Canada
Acebutolol-100-tab 100mg	Tablet	100 mg	Oral	Pro Doc Limitee	1996-12-31	Not applicable	Canada
Acebutolol-200 - Tab 200mg	Tablet	200 mg	Oral	Pro Doc Limitee	1996-12-31	Not applicable	Canada
Ava-acebutolol	Tablet	100 mg	Oral	Avanstra Inc	2011-10-11	2014-08-21	Canada
Ava-acebutolol	Tablet	200 mg	Oral	Avanstra Inc	2011-10-11	2014-08-21	Canada
Ava-acebutolol	Tablet	400 mg	Oral	Avanstra Inc	2011-10-11	2014-08-21	Canada
Monitan 100	Tablet	100 mg	Oral	Wyeth Ltd.	1995-12-31	2004-09-13	Canada
Monitan 200	Tablet	200 mg	Oral	Wyeth Ltd.	1995-12-31	2007-01-22	Canada
Monitan 400	Tablet	400 mg	Oral	Wyeth Ltd.	1994-12-31	2007-01-22	Canada
Monitan Tab 200mg	Tablet	200 mg	Oral	Wyeth Ltd.	1987-12-31	1996-09-10	Canada
Monitan Tab 400mg	Tablet	400 mg	Oral	Wyeth Ltd.	1990-12-31	1996-09-10	Canada
Mylan-acebutolol	Tablet	400 mg	Oral	Mylan Pharmaceuticals	1998-04-06	Not applicable	Canada
Mylan-acebutolol	Tablet	100 mg	Oral	Mylan Pharmaceuticals	1998-04-06	Not applicable	Canada
Mylan-acebutolol	Tablet	200 mg	Oral	Mylan Pharmaceuticals	1998-04-06	Not applicable	Canada
Mylan-acebutolol (type S)	Tablet	100 mg	Oral	Mylan Pharmaceuticals	1998-09-16	Not applicable	Canada
Mylan-acebutolol (type S)	Tablet	200 mg	Oral	Mylan Pharmaceuticals	1998-09-16	Not applicable	Canada
Mylan-acebutolol (type S)	Tablet	400 mg	Oral	Mylan Pharmaceuticals	1998-09-16	Not applicable	Canada
Novo-acebutolol (type S)	Tablet	400 mg	Oral	Novopharm Limited	Not applicable	Not applicable	Canada
Novo-acebutolol (type S)	Tablet	200 mg	Oral	Novopharm Limited	Not applicable	Not applicable	Canada
Novo-acebutolol (type S)	Tablet	100 mg	Oral	Novopharm Limited	Not applicable	Not applicable	Canada
Nu-acebutolol - Tab 100mg	Tablet	100 mg	Oral	Nu Pharm Inc	1995-12-31	2012-09-04	Canada
Nu-acebutolol - Tab 200mg	Tablet	200 mg	Oral	Nu Pharm Inc	1995-12-31	2012-09-04	Canada
Nu-acebutolol - Tab 400mg	Tablet	400 mg	Oral	Nu Pharm Inc	1995-12-31	2012-09-04	Canada
Penta-acebutolol Tablets	Tablet	400 mg	Oral	Pentapharm Ltd.	Not applicable	Not applicable	Canada
Penta-acebutolol Tablets	Tablet	100 mg	Oral	Pentapharm Ltd.	Not applicable	Not applicable	Canada
Penta-acebutolol Tablets	Tablet	200 mg	Oral	Pentapharm Ltd.	Not applicable	Not applicable	Canada
Rhotral 100	Tablet	100 mg	Oral	Sanofi Aventis	1991-12-31	2010-10-26	Canada
Rhotral 200	Tablet	200 mg	Oral	Sanofi Aventis	1991-12-31	2010-10-26	Canada
Rhotral 400	Tablet	400 mg	Oral	Sanofi Aventis	1995-12-31	2011-01-06	Canada
Sandoz Acebutolol	Tablet	400 mg	Oral	Sandoz Canada Incorporated	2004-08-18	2017-05-17	Canada
Sandoz Acebutolol	Tablet	100 mg	Oral	Sandoz Canada Incorporated	2004-08-18	2017-05-17	Canada
Sandoz Acebutolol	Tablet	200 mg	Oral	Sandoz Canada Incorporated	2004-08-18	2017-05-17	Canada
Sectral	Capsule	200 mg/1	Oral	Promius Pharma, LLC	1984-12-28	Not applicable	US
Sectral	Tablet	400 mg	Oral	Sanofi Aventis	1990-12-31	2017-03-30	Canada
Sectral	Tablet	200 mg	Oral	Sanofi Aventis	1986-12-31	Not applicable	Canada
Sectral	Capsule	400 mg/1	Oral	Promius Pharma, LLC	1984-12-28	Not applicable	US
Sectral	Tablet	100 mg	Oral	Sanofi Aventis	1986-12-31	Not applicable	Canada
Teva-acebutolol	Tablet	400 mg	Oral	Teva	1996-08-16	Not applicable	Canada
Teva-acebutolol	Tablet	200 mg	Oral	Teva	1996-08-16	Not applicable	Canada
Teva-acebutolol	Tablet	100 mg	Oral	Teva	1996-08-16	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Acebutolol Hydrochloride	Capsule	200 mg/1	Oral	Mylan Pharmaceuticals	1995-04-24	Not applicable	US
Acebutolol Hydrochloride	Capsule	200 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2009-12-01	Not applicable	US
Acebutolol Hydrochloride	Capsule	200 mg/1	Oral	Av Kare, Inc.	2009-12-14	Not applicable	US
Acebutolol Hydrochloride	Capsule	400 mg/1	Oral	Physicians Total Care, Inc.	2005-04-22	Not applicable	US
Acebutolol Hydrochloride	Capsule	400 mg/1	Oral	Mylan Pharmaceuticals	1995-04-24	Not applicable	US
Acebutolol Hydrochloride	Capsule	400 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2009-12-01	Not applicable	US
Acebutolol Hydrochloride	Capsule	200 mg/1	Oral	Av Pak	2009-12-01	Not applicable	US
Acebutolol Hydrochloride	Capsule	400 mg/1	Oral	Av Kare, Inc.	2009-12-14	Not applicable	US
Acebutolol Hydrochloride	Capsule	200 mg/1	Oral	bryant ranch prepack	2009-12-01	Not applicable	US
Acebutolol Hydrochloride	Capsule	200 mg/1	Oral	Major	2009-12-01	Not applicable	US
Acebutolol Hydrochloride	Capsule	400 mg/1	Oral	Av Pak	2009-12-01	2016-10-13	US
Apo-acebutolol	Tablet	400 mg	Oral	Apotex Corporation	1995-12-31	Not applicable	Canada
Apo-acebutolol	Tablet	200 mg	Oral	Apotex Corporation	1995-12-31	Not applicable	Canada
Apo-acebutolol	Tablet	100 mg	Oral	Apotex Corporation	1995-12-31	Not applicable	Canada

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Prent	Bayer

Brand mixtures

Not Available

Categories

UNII

67P356D8GH

CAS number

37517-30-9

Weight

Average: 336.4259
Monoisotopic: 336.204907394

Chemical Formula

C₁₈H₂₈N₂O₄

InChI Key

GOEMGAFJFRBGGG-UHFFFAOYSA-N

InChI

InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)

IUPAC Name

N-(3-acetyl-4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)butanamide

SMILES

CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1

Pharmacology

Indication

For the management of hypertension and ventricular premature beats in adults.

Structured Indications

Pharmacodynamics

Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. In general, beta-blockers reduce the work the heart has to do and allow it to beat more regularly. Acebutolol has less antagonistic effects on peripheral vascular ß2-receptors at rest and after epinephrine stimulation than nonselective beta-antagonists. Low doses of acebutolol produce less evidence of bronchoconstriction than nonselective agents like propranolol but more than atenolol.

Mechanism of action

Acebutolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors, lowering the heart rate and blood pressure. This drug then has the reverse effect of epinephrine. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Beta-1 adrenergic receptor	Protein	yes	partial agonist	Human	P08588	details
Beta-2 adrenergic receptor	Protein	unknown	partial agonist	Human	P07550	details

Absorption

Well absorbed from the Gl tract with an absolute bioavailability of approximately 40% for the parent compound. In

Volume of distribution

Not Available

Protein binding

26%

Metabolism

Subject to extensive first-pass hepatic biotransformation (primarily to diacetolol).

Route of elimination

Elimination via renal excretion is approximately 30% to 40% and by non-renal mechanisms 50% to 60%, which includes excretion into the bile and direct passage through the intestinal wall.

Half life

The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.

Clearance

Not Available

Toxicity

Symptoms of overdose include extreme bradycardia, advanced atrioventricular block, intraventricular conduction defects, hypotension, severe congestive heart failure, seizures, and in susceptible patients, bronchospasm, and hypoglycemia.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Acebutolol Action Pathway	Drug action	SMP00296

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	1,10-Phenanthroline may increase the bradycardic activities of Acebutolol.	Experimental
4-Methoxyamphetamine	4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Acebutolol.	Experimental
Aceclofenac	Aceclofenac may decrease the antihypertensive activities of Acebutolol.	Approved
Acepromazine	Acepromazine may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Aceprometazine	Aceprometazine may increase the hypotensive activities of Acebutolol.	Approved
Acetaminophen	The serum concentration of Acebutolol can be increased when it is combined with Acetaminophen.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Acebutolol is combined with Acetazolamide.	Approved, Vet Approved
Acetohexamide	Acebutolol may increase the hypoglycemic activities of Acetohexamide.	Withdrawn
Acetylcholine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Acetylcholine.	Approved
Acetyldigitoxin	Acebutolol may increase the bradycardic activities of Acetyldigitoxin.	Approved
Acetylsalicylic acid	Acetylsalicylic acid may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved
Adapalene	Adapalene may decrease the antihypertensive activities of Acebutolol.	Approved
Afatinib	The serum concentration of Acebutolol can be increased when it is combined with Afatinib.	Approved
Agmatine	Agmatine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Experimental, Investigational
Albendazole	The serum concentration of Acebutolol can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.	Approved
Aldosterone	The serum concentration of Acebutolol can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Acebutolol can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Acebutolol can be increased when it is combined with Alfentanil.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Alimemazine	Alimemazine may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Aliskiren	The risk or severity of adverse effects can be increased when Acebutolol is combined with Aliskiren.	Approved, Investigational
Alprenolol	Alprenolol may increase the hypotensive activities of Acebutolol.	Approved, Withdrawn
Amantadine	The serum concentration of Acebutolol can be increased when it is combined with Amantadine.	Approved
Ambenonium	Ambenonium may increase the bradycardic activities of Acebutolol.	Approved
Ambrisentan	Acebutolol may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Ambroxol acefyllinate	Acebutolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.	Experimental
Amifostine	Acebutolol may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Acebutolol.	Approved
Aminohippuric acid	The serum concentration of Acebutolol can be increased when it is combined with Aminohippuric acid.	Approved
Aminophylline	Acebutolol may decrease the bronchodilatory activities of Aminophylline.	Approved
Amiodarone	Amiodarone may increase the bradycardic activities of Acebutolol.	Approved, Investigational
Amitriptyline	The serum concentration of Acebutolol can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Acebutolol.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Acebutolol.	Approved, Illicit
Amodiaquine	The metabolism of Acebutolol can be decreased when combined with Amodiaquine.	Approved
Amphetamine	The risk or severity of adverse effects can be increased when Amphetamine is combined with Acebutolol.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Acebutolol is combined with Amphotericin B.	Approved, Investigational
Amprenavir	The serum concentration of Acebutolol can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Acebutolol can be increased when it is combined with Amsacrine.	Approved
Amyl Nitrite	The risk or severity of adverse effects can be increased when Acebutolol is combined with Amyl Nitrite.	Approved
Andrographolide	HMPL-004 may decrease the antihypertensive activities of Acebutolol.	Investigational
Anisodamine	Anisodamine may decrease the antihypertensive activities of Acebutolol.	Investigational
Antipyrine	Antipyrine may decrease the antihypertensive activities of Acebutolol.	Approved
Apocynin	Acetovanillone may decrease the antihypertensive activities of Acebutolol.	Investigational
Apomorphine	Apomorphine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Apraclonidine is combined with Acebutolol.	Approved
Apremilast	Apremilast may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Arbutamine	Acebutolol may decrease the bronchodilatory activities of Arbutamine.	Approved
Arecoline	The risk or severity of adverse effects can be increased when Acebutolol is combined with Arecoline.	Experimental
Arformoterol	Acebutolol may decrease the bronchodilatory activities of Arformoterol.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Arotinolol.	Approved
Arsenic trioxide	The risk or severity of adverse effects can be increased when Acebutolol is combined with Arsenic trioxide.	Approved, Investigational
Astemizole	The serum concentration of Acebutolol can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Acebutolol can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The risk or severity of adverse effects can be increased when Atenolol is combined with Acebutolol.	Approved
Atomoxetine	Atomoxetine may increase the hypertensive activities of Acebutolol.	Approved
Atorvastatin	The serum concentration of Acebutolol can be increased when it is combined with Atorvastatin.	Approved
Azapropazone	Azapropazone may decrease the antihypertensive activities of Acebutolol.	Withdrawn
Azelastine	The serum concentration of Acebutolol can be increased when it is combined with Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Acebutolol is combined with Azilsartan medoxomil.	Approved
Azithromycin	The serum concentration of Acebutolol can be increased when it is combined with Azithromycin.	Approved
Balsalazide	Balsalazide may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Bambuterol	Acebutolol may decrease the bronchodilatory activities of Bambuterol.	Approved
Barbexaclone	Barbexaclone may increase the hypotensive activities of Acebutolol.	Experimental
Barbital	Barbital may increase the hypotensive activities of Acebutolol.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Barnidipine.	Approved
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Acebutolol.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acebutolol.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Acebutolol.	Withdrawn
Benoxaprofen	Benoxaprofen may decrease the antihypertensive activities of Acebutolol.	Withdrawn
Benzocaine	The serum concentration of Acebutolol can be increased when it is combined with Benzocaine.	Approved
Benzphetamine	Benzphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Illicit
Bepridil	The serum concentration of Acebutolol can be increased when it is combined with Bepridil.	Approved, Withdrawn
Beractant	Acebutolol may increase the bradycardic activities of Beractant.	Approved
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Acebutolol.	Approved
Bethanechol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Bethanechol.	Approved
Bethanidine	Bethanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Betulinic Acid	Betulinic Acid may decrease the antihypertensive activities of Acebutolol.	Investigational
Bimatoprost	Bimatoprost may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Biperiden	The serum concentration of Acebutolol can be increased when it is combined with Biperiden.	Approved
Bisoprolol	The risk or severity of adverse effects can be increased when Bisoprolol is combined with Acebutolol.	Approved
BL-1020	BL-1020 may increase the hypotensive activities of Acebutolol.	Investigational
Bortezomib	The risk or severity of adverse effects can be increased when Acebutolol is combined with Bortezomib.	Approved, Investigational
Bosentan	Bosentan may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Bosutinib	The serum concentration of Acebutolol can be increased when it is combined with Bosutinib.	Approved
Bretylium	Bretylium may increase the bradycardic activities of Acebutolol.	Approved
Brimonidine	Brimonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Acebutolol.	Approved
Bromfenac	Bromfenac may decrease the antihypertensive activities of Acebutolol.	Approved
Bromocriptine	Bromocriptine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Investigational
Bucillamine	Bucillamine may decrease the antihypertensive activities of Acebutolol.	Investigational
Bucindolol	Acebutolol may increase the orthostatic hypotensive activities of Bucindolol.	Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol.	Approved
Bupivacaine	The serum concentration of Bupivacaine can be increased when it is combined with Acebutolol.	Approved, Investigational
Bupranolol	Acebutolol may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	The serum concentration of Acebutolol can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Acebutolol can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The serum concentration of Acebutolol can be increased when it is combined with Cabazitaxel.	Approved
Cabergoline	Acebutolol may increase the vasoconstricting activities of Cabergoline.	Approved
Caffeine	The serum concentration of Acebutolol can be increased when it is combined with Caffeine.	Approved
Calfactant	Acebutolol may increase the bradycardic activities of Calfactant.	Approved
Canagliflozin	The risk or severity of adverse effects can be increased when Acebutolol is combined with Canagliflozin.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Acebutolol.	Approved
Candoxatril	Candoxatril may increase the hypotensive activities of Acebutolol.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Acebutolol is combined with Captopril.	Approved
Carbachol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Carbachol.	Approved
Carbamazepine	The serum concentration of Acebutolol can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Acebutolol is combined with Carbetocin.	Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Acebutolol.	Withdrawn
Carprofen	Carprofen may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved, Withdrawn
Carteolol	The risk or severity of adverse effects can be increased when Carteolol is combined with Acebutolol.	Approved
Carvedilol	Acebutolol may increase the orthostatic hypotensive activities of Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Acebutolol can be increased when it is combined with Caspofungin.	Approved
Castanospermine	Castanospermine may decrease the antihypertensive activities of Acebutolol.	Experimental
Celecoxib	Celecoxib may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Celiprolol	Acebutolol may decrease the bronchodilatory activities of Celiprolol.	Approved, Investigational
Ceritinib	Acebutolol may increase the bradycardic activities of Ceritinib.	Approved
Cevimeline	The risk or severity of adverse effects can be increased when Acebutolol is combined with Cevimeline.	Approved
Chloroquine	The serum concentration of Acebutolol can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acebutolol.	Approved, Vet Approved
Chlorphentermine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	The serum concentration of Acebutolol can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Acebutolol can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Acebutolol can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acebutolol.	Approved
Cholesterol	The serum concentration of Acebutolol can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Acebutolol can be decreased when it is combined with Cholic Acid.	Approved
Choline magnesium trisalicylate	Trisalicylate-choline may decrease the antihypertensive activities of Acebutolol.	Approved
Cilazapril	The risk or severity of adverse effects can be increased when Acebutolol is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Cilnidipine.	Approved
Cimetidine	The serum concentration of Acebutolol can be decreased when it is combined with Cimetidine.	Approved
Ciprofloxacin	The serum concentration of Acebutolol can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Citalopram	The serum concentration of Acebutolol can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Acebutolol can be increased when it is combined with Clarithromycin.	Approved
Clenbuterol	Acebutolol may decrease the bronchodilatory activities of Clenbuterol.	Approved, Vet Approved
Clevidipine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine.	Approved
Clofarabine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Clofarabine.	Approved, Investigational
Clofazimine	The serum concentration of Acebutolol can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Acebutolol can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clonidine	Clonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Clonixin	Clonixin may decrease the antihypertensive activities of Acebutolol.	Approved
Clotrimazole	The serum concentration of Acebutolol can be decreased when it is combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Clozapine.	Approved
Cobicistat	The serum concentration of Acebutolol can be increased when it is combined with Cobicistat.	Approved
Colchicine	The serum concentration of Acebutolol can be increased when it is combined with Colchicine.	Approved
Colforsin	The serum concentration of Acebutolol can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The risk or severity of adverse effects can be increased when Acebutolol is combined with Conivaptan.	Approved, Investigational
Crizotinib	The serum concentration of Acebutolol can be increased when it is combined with Crizotinib.	Approved
Cryptenamine	Cryptenamine may increase the hypotensive activities of Acebutolol.	Approved
Curcumin	Curcumin may decrease the antihypertensive activities of Acebutolol.	Investigational
Cyclophosphamide	The serum concentration of Acebutolol can be increased when it is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Acebutolol can be decreased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Acebutolol.	Approved
Daclatasvir	The serum concentration of Acebutolol can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Acebutolol can be increased when it is combined with Dactinomycin.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin.	Approved
Dapoxetine	The serum concentration of Acebutolol can be increased when it is combined with Dapoxetine.	Investigational
Dasatinib	The serum concentration of Acebutolol can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Acebutolol can be decreased when it is combined with Daunorubicin.	Approved
Debrisoquin	Acebutolol may increase the hypotensive activities of Debrisoquin.	Approved
Decamethonium	Decamethonium may increase the bradycardic activities of Acebutolol.	Approved
Demecarium	Demecarium may increase the bradycardic activities of Acebutolol.	Approved
Deserpidine	Acebutolol may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Acebutolol is combined with Desflurane.	Approved
Desipramine	The serum concentration of Acebutolol can be increased when it is combined with Desipramine.	Approved
Deslanoside	Acebutolol may increase the bradycardic activities of Deslanoside.	Approved
Desloratadine	The serum concentration of Acebutolol can be increased when it is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The serum concentration of Acebutolol can be increased when it is combined with Desvenlafaxine.	Approved
Dexamethasone	The serum concentration of Acebutolol can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexmedetomidine	Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Vet Approved
Dextromethorphan	The serum concentration of Acebutolol can be increased when it is combined with Dextromethorphan.	Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Acebutolol.	Approved
Diclofenac	The serum concentration of Acebutolol can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Diclofenamide is combined with Acebutolol.	Approved
Diflunisal	Diflunisal may decrease the antihypertensive activities of Acebutolol.	Approved
Digitoxin	Acebutolol may increase the bradycardic activities of Digitoxin.	Approved
Digoxin	The serum concentration of Acebutolol can be decreased when it is combined with Digoxin.	Approved
Dihydralazine	Acebutolol may increase the hypotensive activities of Dihydralazine.	Investigational
Dihydroergotamine	Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Diltiazem	The risk or severity of adverse effects can be increased when Diltiazem is combined with Acebutolol.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.	Approved
Dipivefrin	Dipivefrin may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Dipyridamole	Dipyridamole may increase the bradycardic activities of Acebutolol.	Approved
Disopyramide	Disopyramide may increase the bradycardic activities of Acebutolol.	Approved
Dobutamine	Acebutolol may decrease the bronchodilatory activities of Dobutamine.	Approved
Donepezil	Donepezil may increase the bradycardic activities of Acebutolol.	Approved
Dopamine	The risk or severity of adverse effects can be increased when Dopamine is combined with Acebutolol.	Approved
Dorzolamide	Dorzolamide may increase the hypotensive activities of Acebutolol.	Approved
Doxazosin	Acebutolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Doxepin	The serum concentration of Acebutolol can be increased when it is combined with Doxepin.	Approved
Doxofylline	The risk or severity of adverse effects can be increased when Acebutolol is combined with Doxofylline.	Approved
Doxorubicin	The serum concentration of Acebutolol can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Dronabinol	The serum concentration of Acebutolol can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	Dronedarone may increase the bradycardic activities of Acebutolol.	Approved
Droxicam	Droxicam may decrease the antihypertensive activities of Acebutolol.	Approved
Droxidopa	Droxidopa may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Investigational
Duloxetine	Acebutolol may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Duvelisib	Duvelisib may decrease the antihypertensive activities of Acebutolol.	Investigational
Dyphylline	Acebutolol may decrease the bronchodilatory activities of Dyphylline.	Approved
E-6201	E6201 may decrease the antihypertensive activities of Acebutolol.	Investigational
Ebselen	Ebselen may decrease the antihypertensive activities of Acebutolol.	Investigational
Echothiophate	Echothiophate may increase the bradycardic activities of Acebutolol.	Approved
Edrophonium	Edrophonium may increase the bradycardic activities of Acebutolol.	Approved
Efonidipine	Acebutolol may increase the hypotensive activities of Efonidipine.	Approved
Elbasvir	The serum concentration of Acebutolol can be increased when it is combined with Elbasvir.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Acebutolol.	Approved, Vet Approved
Enalaprilat	Acebutolol may increase the hypotensive activities of Enalaprilat.	Approved
Enzalutamide	The serum concentration of Acebutolol can be increased when it is combined with Enzalutamide.	Approved
Ephedra	Ephedra may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Nutraceutical, Withdrawn
Ephedrine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Ephedrine.	Approved
Epibatidine	The risk or severity of adverse effects can be increased when Acebutolol is combined with EPIBATIDINE.	Experimental
Epinephrine	Epinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Vet Approved
Epirizole	Epirizole may decrease the antihypertensive activities of Acebutolol.	Approved
Eplerenone	The risk or severity of adverse effects can be increased when Eplerenone is combined with Acebutolol.	Approved
Epoprostenol	Acebutolol may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Acebutolol.	Approved
Ergoloid mesylate	Acebutolol may increase the vasoconstricting activities of Ergoloid mesylate.	Approved
Ergonovine	Acebutolol may increase the vasoconstricting activities of Ergonovine.	Approved
Ergotamine	Ergotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Erythromycin	The serum concentration of Acebutolol can be decreased when it is combined with Erythromycin.	Approved, Vet Approved
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Acebutolol.	Approved
Estramustine	The serum concentration of Acebutolol can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Acebutolol can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Acebutolol can be decreased when it is combined with Estrone.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.	Approved
Etanercept	Etanercept may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Etilefrine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Etilefrine.	Withdrawn
Etodolac	Etodolac may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational, Vet Approved
Etofenamate	Etofenamate may decrease the antihypertensive activities of Acebutolol.	Approved
Etomidate	Etomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Etoperidone	The serum concentration of Acebutolol can be increased when it is combined with Etoperidone.	Approved
Etoposide	The serum concentration of Acebutolol can be increased when it is combined with Etoposide.	Approved
Etoricoxib	Etoricoxib may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Etravirine	The serum concentration of Acebutolol can be increased when it is combined with Etravirine.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Acebutolol.	Approved, Investigational
Fenbufen	Fenbufen may decrease the antihypertensive activities of Acebutolol.	Approved
Fenoldopam	Fenoldopam may increase the hypotensive activities of Acebutolol.	Approved
Fenoprofen	Fenoprofen may decrease the antihypertensive activities of Acebutolol.	Approved
Fenoterol	Acebutolol may decrease the bronchodilatory activities of Fenoterol.	Approved
Fentanyl	The serum concentration of Acebutolol can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol.	Approved
Fexofenadine	The serum concentration of Acebutolol can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Acebutolol can be increased when it is combined with Fidaxomicin.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Acebutolol is combined with Fimasartan.	Approved
Fingolimod	Acebutolol may increase the bradycardic activities of Fingolimod.	Approved, Investigational
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Acebutolol.	Approved, Withdrawn
Fluconazole	The serum concentration of Acebutolol can be increased when it is combined with Fluconazole.	Approved
Fluoxetine	The serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Acebutolol can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Acebutolol can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Acebutolol can be increased when it is combined with Flurazepam.	Approved, Illicit
Flurbiprofen	Flurbiprofen may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Fluvoxamine	The serum concentration of Acebutolol can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Formoterol	Acebutolol may decrease the bronchodilatory activities of Formoterol.	Approved, Investigational
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Acebutolol.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol.	Approved, Vet Approved
Galantamine	Galantamine may increase the bradycardic activities of Acebutolol.	Approved
Gallamine Triethiodide	Gallamine Triethiodide may increase the bradycardic activities of Acebutolol.	Approved
Gefitinib	The serum concentration of Acebutolol can be increased when it is combined with Gefitinib.	Approved, Investigational
Genistein	The serum concentration of Acebutolol can be increased when it is combined with Genistein.	Investigational
Ginkgo biloba	Ginkgo biloba may increase the bradycardic activities of Acebutolol.	Approved, Nutraceutical
Glibornuride	Acebutolol may increase the hypoglycemic activities of Glibornuride.	Withdrawn
Gliclazide	Acebutolol may increase the hypoglycemic activities of Gliclazide.	Approved
Glimepiride	Acebutolol may increase the hypoglycemic activities of Glimepiride.	Approved
Glipizide	Acebutolol may increase the hypoglycemic activities of Glipizide.	Approved
Gliquidone	Acebutolol may increase the hypoglycemic activities of Gliquidone.	Approved
Glisoxepide	Acebutolol may increase the hypoglycemic activities of Glisoxepide.	Approved
Glyburide	The serum concentration of Acebutolol can be increased when it is combined with Glyburide.	Approved
Gramicidin D	The serum concentration of Acebutolol can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The serum concentration of Acebutolol can be increased when it is combined with Grepafloxacin.	Withdrawn
GTS-21	The risk or severity of adverse effects can be increased when Acebutolol is combined with GTS-21.	Investigational
Guanabenz	Guanabenz may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Guanadrel	Guanadrel may increase the hypotensive activities of Acebutolol.	Approved
Guanethidine	Guanethidine may increase the hypotensive activities of Acebutolol.	Approved
Guanfacine	Guanfacine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Investigational
Haloperidol	The serum concentration of Acebutolol can be increased when it is combined with Haloperidol.	Approved
Halothane	The risk or severity of adverse effects can be increased when Acebutolol is combined with Halothane.	Approved, Vet Approved
Hexamethonium	Acebutolol may increase the hypotensive activities of Hexamethonium.	Experimental
Hexobarbital	Hexobarbital may increase the hypotensive activities of Acebutolol.	Approved
Higenamine	Higenamine may decrease the antihypertensive activities of Acebutolol.	Investigational
Huperzine A	Huperzine A may increase the bradycardic activities of Acebutolol.	Investigational
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Acebutolol.	Experimental
Hydralazine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acebutolol.	Approved, Vet Approved
Hydrocortisone	The serum concentration of Acebutolol can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Acebutolol.	Approved
Hydroxyamphetamine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Hydroxyamphetamine hydrobromide.	Approved
Hydroxychloroquine	The metabolism of Acebutolol can be decreased when combined with Hydroxychloroquine.	Approved
Ibuprofen	Ibuprofen may decrease the antihypertensive activities of Acebutolol.	Approved
Ibuproxam	Ibuproxam may decrease the antihypertensive activities of Acebutolol.	Withdrawn
Icatibant	Icatibant may decrease the antihypertensive activities of Acebutolol.	Approved
Idelalisib	The serum concentration of Acebutolol can be increased when it is combined with Idelalisib.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Imatinib	The serum concentration of Acebutolol can be increased when it is combined with Imatinib.	Approved
Imidapril	The risk or severity of adverse effects can be increased when Acebutolol is combined with Imidapril.	Investigational
Imipramine	The serum concentration of Acebutolol can be increased when it is combined with Imipramine.	Approved
Indacaterol	Acebutolol may decrease the bronchodilatory activities of Indacaterol.	Approved
Indalpine	The serum concentration of Acebutolol can be increased when it is combined with Indalpine.	Investigational, Withdrawn
Indapamide	The risk or severity of adverse effects can be increased when Indapamide is combined with Acebutolol.	Approved
Indenolol	Acebutolol may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The serum concentration of Acebutolol can be decreased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Acebutolol can be increased when it is combined with Indomethacin.	Approved, Investigational
Indoprofen	Indoprofen may decrease the antihypertensive activities of Acebutolol.	Withdrawn
Indoramin	Acebutolol may increase the orthostatic hypotensive activities of Indoramin.	Withdrawn
Insulin Pork	Acebutolol may increase the hypoglycemic activities of Insulin Pork.	Approved
Iobenguane	The therapeutic efficacy of Iobenguane can be decreased when used in combination with Acebutolol.	Approved
Iproclozide	Iproclozide may increase the hypotensive activities of Acebutolol.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Acebutolol.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Acebutolol.	Approved, Investigational
Isavuconazonium	The serum concentration of Acebutolol can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Acebutolol.	Approved
Isoetarine	Acebutolol may decrease the bronchodilatory activities of Isoetarine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Acebutolol is combined with Isoflurane.	Approved, Vet Approved
Isoflurophate	Isoflurophate may increase the bradycardic activities of Acebutolol.	Approved, Withdrawn
Isoprenaline	Acebutolol may decrease the bronchodilatory activities of Isoprenaline.	Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Acebutolol.	Approved
Isoxicam	Isoxicam may decrease the antihypertensive activities of Acebutolol.	Withdrawn
Isoxsuprine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Acebutolol.	Approved
Itraconazole	The serum concentration of Acebutolol can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivabradine	Acebutolol may increase the bradycardic activities of Ivabradine.	Approved
Ivacaftor	The serum concentration of Acebutolol can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Acebutolol can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Kebuzone	Kebuzone may decrease the antihypertensive activities of Acebutolol.	Experimental
Ketamine	The serum concentration of Acebutolol can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketanserin	Acebutolol may increase the hypotensive activities of Ketanserin.	Investigational
Ketoconazole	The serum concentration of Acebutolol can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	Ketoprofen may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved
Ketorolac	Ketorolac may decrease the antihypertensive activities of Acebutolol.	Approved
Labetalol	Acebutolol may increase the orthostatic hypotensive activities of Labetalol.	Approved
Lacidipine	Acebutolol may increase the hypotensive activities of Lacidipine.	Approved
Lacosamide	Acebutolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.	Approved
Lanreotide	Acebutolol may increase the bradycardic activities of Lanreotide.	Approved
Lansoprazole	The serum concentration of Acebutolol can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Acebutolol can be increased when it is combined with Lapatinib.	Approved, Investigational
Latanoprost	Latanoprost may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Leflunomide	Leflunomide may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Lercanidipine	Lercanidipine may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Levobupivacaine.	Approved
Levodopa	Acebutolol may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levofloxacin	The serum concentration of Acebutolol can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levomilnacipran	The serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Acebutolol is combined with Levosimendan.	Approved, Investigational
Levothyroxine	The serum concentration of Acebutolol can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Acebutolol can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Linezolid	Linezolid may increase the hypertensive activities of Acebutolol.	Approved, Investigational
Liothyronine	The serum concentration of Acebutolol can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Acebutolol can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Acebutolol.	Approved, Investigational
Lisofylline	Lisofylline may decrease the antihypertensive activities of Acebutolol.	Investigational
Lobeline	The risk or severity of adverse effects can be increased when Acebutolol is combined with Lobeline.	Investigational
Lofexidine	Lofexidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Investigational
Lomitapide	The serum concentration of Acebutolol can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Acebutolol can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of Acebutolol can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Acebutolol can be increased when it is combined with Loratadine.	Approved
Lornoxicam	Lornoxicam may decrease the antihypertensive activities of Acebutolol.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Acebutolol.	Approved
Lovastatin	The serum concentration of Acebutolol can be increased when it is combined with Lovastatin.	Approved, Investigational
Loxoprofen	Loxoprofen may decrease the antihypertensive activities of Acebutolol.	Approved
Lucinactant	Acebutolol may increase the bradycardic activities of Lucinactant.	Approved
Lumacaftor	The serum concentration of Acebutolol can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	Lumiracoxib may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Macitentan	Acebutolol may increase the hypotensive activities of Macitentan.	Approved
Magnesium salicylate	Magnesium salicylate may decrease the antihypertensive activities of Acebutolol.	Approved
Malathion	Malathion may increase the bradycardic activities of Acebutolol.	Approved, Investigational
Manidipine	Acebutolol may increase the hypotensive activities of Manidipine.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.	Approved, Investigational
Maprotiline	The serum concentration of Acebutolol can be increased when it is combined with Maprotiline.	Approved
Masoprocol	Masoprocol may decrease the antihypertensive activities of Acebutolol.	Approved
Mebanazine	Mebanazine may increase the hypotensive activities of Acebutolol.	Withdrawn
Mebendazole	The serum concentration of Acebutolol can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Acebutolol.	Approved
Meclofenamic acid	Meclofenamic acid may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved
Mefenamic acid	Mefenamic acid may decrease the antihypertensive activities of Acebutolol.	Approved
Mefloquine	Mefloquine may increase the bradycardic activities of Acebutolol.	Approved
Megestrol acetate	The serum concentration of Acebutolol can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meloxicam	Meloxicam may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved
Memantine	Memantine may increase the bradycardic activities of Acebutolol.	Approved, Investigational
Mephentermine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Mephentermine.	Approved
Mepivacaine	The serum concentration of Mepivacaine can be increased when it is combined with Acebutolol.	Approved, Vet Approved
Meprobamate	The serum concentration of Acebutolol can be increased when it is combined with Meprobamate.	Approved, Illicit
Mesalazine	Mesalazine may decrease the antihypertensive activities of Acebutolol.	Approved
Mesoridazine	Mesoridazine may increase the hypotensive activities of Acebutolol.	Approved
Metamizole	Metamizole may decrease the antihypertensive activities of Acebutolol.	Withdrawn
Metaraminol	The risk or severity of adverse effects can be increased when Metaraminol is combined with Acebutolol.	Approved, Investigational
Methacholine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Methacholine.	Approved
Methadone	The serum concentration of Acebutolol can be increased when it is combined with Methadone.	Approved
Methamphetamine	Methamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Illicit
Methanesulfonyl Fluoride	Methanesulfonyl Fluoride may increase the bradycardic activities of Acebutolol.	Investigational
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Acebutolol.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Acebutolol.	Approved
Methotrimeprazine	Methotrimeprazine may increase the hypotensive activities of Acebutolol.	Approved
Methoxamine	The risk or severity of adverse effects can be increased when Methoxamine is combined with Acebutolol.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Methyldopa is combined with Acebutolol.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Acebutolol.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Acebutolol.	Approved
Metipranolol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Acebutolol.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Acebutolol.	Approved, Investigational
Metyrosine	Acebutolol may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	The serum concentration of Acebutolol can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Acebutolol can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Acebutolol can be decreased when it is combined with Midazolam.	Approved, Illicit
Midodrine	Acebutolol may increase the bradycardic activities of Midodrine.	Approved
Mifepristone	The serum concentration of Acebutolol can be decreased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	The serum concentration of Acebutolol can be increased when it is combined with Milnacipran.	Approved
Minaprine	Minaprine may increase the bradycardic activities of Acebutolol.	Approved
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Acebutolol.	Approved
Mitomycin	The serum concentration of Acebutolol can be increased when it is combined with Mitomycin.	Approved
Mitoxantrone	The serum concentration of Acebutolol can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Mizoribine	Mizoribine may decrease the antihypertensive activities of Acebutolol.	Investigational
Moclobemide	Moclobemide may increase the hypotensive activities of Acebutolol.	Approved
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Acebutolol.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Acebutolol.	Approved
Moricizine	Moricizine may increase the hypotensive activities of Acebutolol.	Approved, Withdrawn
Morphine	The serum concentration of Acebutolol can be increased when it is combined with Morphine.	Approved, Investigational
Moxonidine	Acebutolol may increase the hypotensive activities of Moxonidine.	Approved
Mycophenolate mofetil	Mycophenolate mofetil may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Mycophenolic acid	Mycophenolic acid may decrease the antihypertensive activities of Acebutolol.	Approved
Nabilone	Nabilone may increase the tachycardic activities of Acebutolol.	Approved, Investigational
Nabumetone	Nabumetone may decrease the antihypertensive activities of Acebutolol.	Approved
Nadolol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Nadolol.	Approved
Nafamostat	Nafamostat may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Naftifine	Naftifine may decrease the antihypertensive activities of Acebutolol.	Approved
Naftopidil	Acebutolol may increase the hypotensive activities of Naftopidil.	Investigational
Naltrexone	The serum concentration of Acebutolol can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naphazoline	Naphazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Naproxen	Naproxen may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved
Naringenin	The serum concentration of Acebutolol can be increased when it is combined with Naringenin.	Experimental
NCX 4016	NCX 4016 may decrease the antihypertensive activities of Acebutolol.	Investigational
Nebivolol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Nebivolol.	Approved, Investigational
Nefazodone	The serum concentration of Acebutolol can be decreased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Acebutolol can be decreased when it is combined with Nelfinavir.	Approved
Neostigmine	Neostigmine may increase the bradycardic activities of Acebutolol.	Approved, Vet Approved
Nepafenac	Nepafenac may decrease the antihypertensive activities of Acebutolol.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Acebutolol is combined with Nesiritide.	Approved, Investigational
Nialamide	Nialamide may increase the hypotensive activities of Acebutolol.	Withdrawn
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Acebutolol.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Acebutolol.	Approved
Nicotine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Nicotine.	Approved
Nifedipine	Nifedipine may increase the hypotensive activities of Acebutolol.	Approved
Niflumic Acid	Niflumic Acid may decrease the antihypertensive activities of Acebutolol.	Approved
Niguldipine	Acebutolol may increase the hypotensive activities of Niguldipine.	Experimental
Nilotinib	The serum concentration of Acebutolol can be increased when it is combined with Nilotinib.	Approved, Investigational
Nilvadipine	Acebutolol may increase the hypotensive activities of Nilvadipine.	Approved
Nimesulide	Nimesulide may decrease the antihypertensive activities of Acebutolol.	Approved, Withdrawn
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Acebutolol.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Acebutolol.	Approved
Nitrazepam	The serum concentration of Acebutolol can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Acebutolol can be increased when it is combined with Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Acebutolol is combined with Nitric Oxide.	Approved
Nitroaspirin	Nitroaspirin may decrease the antihypertensive activities of Acebutolol.	Investigational
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Acebutolol.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Acebutolol.	Approved
Norepinephrine	Norepinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Norethisterone	The serum concentration of Acebutolol can be decreased when it is combined with Norethisterone.	Approved
Obinutuzumab	Acebutolol may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Acebutolol.	Withdrawn
Octreotide	Octreotide may increase the bradycardic activities of Acebutolol.	Approved, Investigational
Oleandrin	Acebutolol may increase the bradycardic activities of Anvirzel.	Experimental
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Acebutolol.	Approved, Investigational
Olodaterol	Acebutolol may decrease the bronchodilatory activities of Olodaterol.	Approved
Olopatadine	Olopatadine may decrease the antihypertensive activities of Acebutolol.	Approved
Olsalazine	Olsalazine may decrease the antihypertensive activities of Acebutolol.	Approved
Omapatrilat	Omapatrilat may increase the hypotensive activities of Acebutolol.	Investigational
Omeprazole	The serum concentration of Acebutolol can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Orciprenaline	Acebutolol may decrease the bronchodilatory activities of Orciprenaline.	Approved
Ouabain	Acebutolol may increase the bradycardic activities of Ouabain.	Approved
Oxaprozin	Oxaprozin may decrease the antihypertensive activities of Acebutolol.	Approved
Oxprenolol	Acebutolol may increase the hypotensive activities of Oxprenolol.	Approved
Oxymetazoline	Oxymetazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Oxyphenbutazone	Oxyphenbutazone may decrease the antihypertensive activities of Acebutolol.	Withdrawn
P-Nitrophenol	The serum concentration of Acebutolol can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of Acebutolol can be increased when it is combined with Paclitaxel.	Approved, Vet Approved
Paliperidone	Paliperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Palmitic Acid	The serum concentration of Acebutolol can be increased when it is combined with Palmitic Acid.	Experimental
Pantoprazole	The serum concentration of Acebutolol can be increased when it is combined with Pantoprazole.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol.	Approved
Parecoxib	Parecoxib may decrease the antihypertensive activities of Acebutolol.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Acebutolol.	Approved
Paroxetine	The serum concentration of Acebutolol can be increased when it is combined with Paroxetine.	Approved, Investigational
Pasireotide	Acebutolol may increase the bradycardic activities of Pasireotide.	Approved
Penbutolol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Penbutolol.	Approved, Investigational
Pentobarbital	Pentobarbital may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Pentolinium	Pentolinium may increase the hypotensive activities of Acebutolol.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Perazine	Perazine may increase the hypotensive activities of Acebutolol.	Investigational
Pergolide	Pergolide may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Vet Approved, Withdrawn
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Acebutolol.	Approved
Perphenazine	Perphenazine may increase the hypotensive activities of Acebutolol.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Acebutolol.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Acebutolol.	Withdrawn
Phenmetrazine	The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol.	Approved, Illicit
Phenobarbital	The serum concentration of Acebutolol can be decreased when it is combined with Phenobarbital.	Approved
Phenoxybenzamine	Phenoxybenzamine may increase the hypotensive activities of Acebutolol.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Acebutolol.	Withdrawn
Phentermine	The risk or severity of adverse effects can be increased when Phentermine is combined with Acebutolol.	Approved, Illicit
Phentolamine	Phentolamine may increase the hypotensive activities of Acebutolol.	Approved
Phenylbutazone	Phenylbutazone may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved
Phenylephrine	The risk or severity of adverse effects can be increased when Phenylephrine is combined with Acebutolol.	Approved
Phenylpropanolamine	Phenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Vet Approved, Withdrawn
Physostigmine	Physostigmine may increase the bradycardic activities of Acebutolol.	Approved
Pilocarpine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Pilocarpine.	Approved
Pimecrolimus	Pimecrolimus may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Pimozide	The serum concentration of Acebutolol can be increased when it is combined with Pimozide.	Approved
Pindolol	The risk or severity of adverse effects can be increased when Pindolol is combined with Acebutolol.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Acebutolol is combined with Pipamperone.	Approved
Pirbuterol	Acebutolol may decrease the bronchodilatory activities of Pirbuterol.	Approved
Pirfenidone	Pirfenidone may decrease the antihypertensive activities of Acebutolol.	Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Acebutolol.	Approved
Piroxicam	Piroxicam may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Acebutolol.	Withdrawn
Platelet Activating Factor	The serum concentration of Acebutolol can be decreased when it is combined with Platelet Activating Factor.	Experimental
Polythiazide	Acebutolol may increase the hypotensive activities of Polythiazide.	Approved
Ponatinib	The serum concentration of Acebutolol can be increased when it is combined with Ponatinib.	Approved
Poractant alfa	Acebutolol may increase the bradycardic activities of Poractant alfa.	Approved
Posaconazole	The serum concentration of Acebutolol can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	The risk or severity of adverse effects can be increased when Acebutolol is combined with Pramipexole.	Approved, Investigational
Pravastatin	The serum concentration of Acebutolol can be increased when it is combined with Pravastatin.	Approved
Prazosin	Acebutolol may increase the orthostatic hypotensive activities of Prazosin.	Approved
Prednisone	The serum concentration of Acebutolol can be increased when it is combined with Prednisone.	Approved, Vet Approved
Primaquine	The metabolism of Acebutolol can be decreased when combined with Primaquine.	Approved
Primidone	Primidone may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Probenecid	The serum concentration of Acebutolol can be increased when it is combined with Probenecid.	Approved
Procaterol	Acebutolol may decrease the bronchodilatory activities of Procaterol.	Approved
Prochlorperazine	Prochlorperazine may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Progesterone	The serum concentration of Acebutolol can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Promazine	Promazine may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Promethazine	The serum concentration of Acebutolol can be increased when it is combined with Promethazine.	Approved
Propacetamol	Propacetamol may decrease the antihypertensive activities of Acebutolol.	Approved
Propafenone	The serum concentration of Acebutolol can be increased when it is combined with Propafenone.	Approved
Propofol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Propofol.	Approved, Investigational, Vet Approved
Propranolol	The risk or severity of adverse effects can be increased when Propranolol is combined with Acebutolol.	Approved, Investigational
Protriptyline	The serum concentration of Acebutolol can be increased when it is combined with Protriptyline.	Approved
Pseudoephedrine	Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
PTC299	PTC299 may decrease the antihypertensive activities of Acebutolol.	Investigational
Pyridostigmine	Pyridostigmine may increase the bradycardic activities of Acebutolol.	Approved
Quercetin	The serum concentration of Acebutolol can be increased when it is combined with Quercetin.	Experimental
Quetiapine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Quetiapine.	Approved
Quinacrine	The serum concentration of Acebutolol can be increased when it is combined with Quinacrine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Acebutolol.	Approved, Investigational
Quinidine	The serum concentration of Acebutolol can be increased when it is combined with Quinidine.	Approved
Quinine	Quinine may increase the hypotensive activities of Acebutolol.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Acebutolol.	Approved
Ranitidine	The serum concentration of Acebutolol can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Acebutolol can be increased when it is combined with Ranolazine.	Approved, Investigational
Rasagiline	Rasagiline may increase the hypotensive activities of Acebutolol.	Approved
Reboxetine	The serum concentration of Acebutolol can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	Regorafenib may increase the bradycardic activities of Acebutolol.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Acebutolol is combined with Remifentanil.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Acebutolol.	Approved
Rescinnamine	Acebutolol may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	Reserpine may increase the hypotensive activities of Acebutolol.	Approved
Resveratrol	Resveratrol may decrease the antihypertensive activities of Acebutolol.	Experimental, Investigational
Rifampicin	The serum concentration of Acebutolol can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Acebutolol can be decreased when it is combined with Rifapentine.	Approved
Rilmenidine	Acebutolol may increase the hypotensive activities of Rilmenidine.	Investigational
Rilpivirine	The serum concentration of Acebutolol can be increased when it is combined with Rilpivirine.	Approved
Riociguat	The risk or severity of adverse effects can be increased when Acebutolol is combined with Riociguat.	Approved
Risperidone	Acebutolol may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritodrine	Acebutolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Ritonavir	The serum concentration of Acebutolol can be decreased when it is combined with Ritonavir.	Approved, Investigational
Rituximab	Acebutolol may increase the hypotensive activities of Rituximab.	Approved
Rivastigmine	Rivastigmine may increase the bradycardic activities of Acebutolol.	Approved, Investigational
Rofecoxib	Rofecoxib may decrease the antihypertensive activities of Acebutolol.	Investigational, Withdrawn
Rolapitant	The serum concentration of Acebutolol can be increased when it is combined with Rolapitant.	Approved
Ropinirole	Ropinirole may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Ropivacaine.	Approved
Rotigotine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Rotigotine.	Approved
Ruxolitinib	Ruxolitinib may increase the bradycardic activities of Acebutolol.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Acebutolol is combined with Sacubitril.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Acebutolol.	Withdrawn
Salbutamol	Acebutolol may decrease the bronchodilatory activities of Salbutamol.	Approved, Vet Approved
Salicylamide	Salicylamide may decrease the antihypertensive activities of Acebutolol.	Approved
Salicylic acid	Salicylic acid may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved
Salmeterol	Acebutolol may decrease the bronchodilatory activities of Salmeterol.	Approved
Salsalate	Salsalate may decrease the antihypertensive activities of Acebutolol.	Approved
Saprisartan	Acebutolol may increase the hypotensive activities of Saprisartan.	Experimental
Saquinavir	The serum concentration of Acebutolol can be decreased when it is combined with Saquinavir.	Approved, Investigational
Scopolamine	The serum concentration of Acebutolol can be increased when it is combined with Scopolamine.	Approved
Secobarbital	Secobarbital may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Selegiline	The serum concentration of Acebutolol can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Selexipag	Acebutolol may increase the hypotensive activities of Selexipag.	Approved
Sertraline	The serum concentration of Acebutolol can be increased when it is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Acebutolol is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Acebutolol.	Approved, Investigational
Silodosin	Acebutolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Simeprevir	The serum concentration of Acebutolol can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Acebutolol can be increased when it is combined with Simvastatin.	Approved
Sirolimus	The serum concentration of Acebutolol can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sitaxentan	Acebutolol may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium Nitrite	The risk or severity of adverse effects can be increased when Acebutolol is combined with Sodium Nitrite.	Approved
Sorafenib	The serum concentration of Acebutolol can be increased when it is combined with Sorafenib.	Approved, Investigational
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Acebutolol.	Approved
Spirapril	Acebutolol may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Acebutolol.	Approved
SRT501	SRT501 may decrease the antihypertensive activities of Acebutolol.	Investigational
St. John's Wort	The serum concentration of Acebutolol can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Acebutolol can be increased when it is combined with Staurosporine.	Experimental
Streptokinase	The risk or severity of adverse effects can be increased when Acebutolol is combined with Streptokinase.	Approved
Streptozocin	The serum concentration of Acebutolol can be decreased when it is combined with Streptozocin.	Approved
Sufentanil	Sufentanil may increase the bradycardic activities of Acebutolol.	Approved, Investigational
Sulfasalazine	Sulfasalazine may decrease the antihypertensive activities of Acebutolol.	Approved
Sulfinpyrazone	The serum concentration of Acebutolol can be increased when it is combined with Sulfinpyrazone.	Approved
Sulindac	Sulindac may decrease the antihypertensive activities of Acebutolol.	Approved
Sumatriptan	The serum concentration of Acebutolol can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Acebutolol can be increased when it is combined with Sunitinib.	Approved, Investigational
Suprofen	Suprofen may decrease the antihypertensive activities of Acebutolol.	Approved, Withdrawn
Synephrine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Synephrine.	Experimental
Tacrine	Tacrine may increase the bradycardic activities of Acebutolol.	Withdrawn
Tacrolimus	The serum concentration of Acebutolol can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tadalafil	Tadalafil may increase the antihypertensive activities of Acebutolol.	Approved, Investigational
Tamoxifen	The serum concentration of Acebutolol can be decreased when it is combined with Tamoxifen.	Approved
Tamsulosin	Acebutolol may increase the orthostatic hypotensive activities of Tamsulosin.	Approved, Investigational
Taurocholic Acid	The serum concentration of Acebutolol can be increased when it is combined with Taurocholic Acid.	Experimental
Tedizolid Phosphate	Tedizolid Phosphate may increase the hypertensive activities of Acebutolol.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Acebutolol.	Approved, Investigational
Temocapril	Acebutolol may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Temsirolimus	The serum concentration of Acebutolol can be increased when it is combined with Temsirolimus.	Approved
Tenoxicam	Tenoxicam may decrease the antihypertensive activities of Acebutolol.	Approved
Terazosin	Acebutolol may increase the orthostatic hypotensive activities of Terazosin.	Approved
Terbutaline	Acebutolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Terfenadine	The serum concentration of Acebutolol can be increased when it is combined with Terfenadine.	Withdrawn
Teriflunomide	Teriflunomide may decrease the antihypertensive activities of Acebutolol.	Approved
Terlipressin	Acebutolol may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Tesmilifene	The serum concentration of Acebutolol can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Acebutolol can be increased when it is combined with Testosterone.	Approved, Investigational
Tetryzoline	The risk or severity of adverse effects can be increased when Acebutolol is combined with Tetryzoline.	Approved
Thalidomide	The risk or severity of adverse effects can be increased when Acebutolol is combined with Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	Acebutolol may decrease the bronchodilatory activities of Theophylline.	Approved
Thiamylal	Thiamylal may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Thiethylperazine	Thiethylperazine may increase the hypotensive activities of Acebutolol.	Withdrawn
Thiopental	Thiopental may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Acebutolol.	Withdrawn
Tiaprofenic acid	Tiaprofenic acid may decrease the antihypertensive activities of Acebutolol.	Approved
Tibolone	Acebutolol may increase the hypotensive activities of Tibolone.	Approved
Ticagrelor	The serum concentration of Acebutolol can be increased when it is combined with Ticagrelor.	Approved
Ticrynafen	Acebutolol may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	The risk or severity of adverse effects can be increased when Timolol is combined with Acebutolol.	Approved
Tinoridine	Tinoridine may decrease the antihypertensive activities of Acebutolol.	Investigational
Tizanidine	Tizanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Tofacitinib	Tofacitinib may increase the bradycardic activities of Acebutolol.	Approved, Investigational
Tolazamide	Acebutolol may increase the hypoglycemic activities of Tolazamide.	Approved
Tolazoline	Tolazoline may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Tolbutamide	Acebutolol may increase the hypoglycemic activities of Tolbutamide.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Acebutolol is combined with Tolcapone.	Approved, Withdrawn
Tolfenamic Acid	Tolfenamic Acid may decrease the antihypertensive activities of Acebutolol.	Approved
Tolmetin	Tolmetin may decrease the antihypertensive activities of Acebutolol.	Approved
Toloxatone	Toloxatone may increase the hypotensive activities of Acebutolol.	Approved
Tolvaptan	The serum concentration of Acebutolol can be increased when it is combined with Tolvaptan.	Approved
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Acebutolol.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Acebutolol.	Approved
Tranilast	Tranilast may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Acebutolol.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Acebutolol.	Approved
Travoprost	Travoprost may increase the hypotensive activities of Acebutolol.	Approved
Trazodone	The serum concentration of Acebutolol can be decreased when it is combined with Trazodone.	Approved, Investigational
Treprostinil	Treprostinil may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Acebutolol is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Acebutolol.	Approved
Trichlormethiazide	Trichlormethiazide may increase the hypotensive activities of Acebutolol.	Approved, Vet Approved
Trifluoperazine	The serum concentration of Acebutolol can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Acebutolol can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimazosin	Acebutolol may increase the orthostatic hypotensive activities of Trimazosin.	Experimental
Trimethaphan	Trimethaphan may increase the hypotensive activities of Acebutolol.	Approved
Trimethoprim	The serum concentration of Acebutolol can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Acebutolol can be increased when it is combined with Trimipramine.	Approved
Tubocurarine	Tubocurarine may increase the bradycardic activities of Acebutolol.	Approved
Tyramine	The risk or severity of adverse effects can be increased when Acebutolol is combined with Tyramine.	Investigational, Nutraceutical
Udenafil	Udenafil may increase the antihypertensive activities of Acebutolol.	Approved, Investigational
Unoprostone	Acebutolol may increase the hypotensive activities of Unoprostone.	Approved
Valdecoxib	Valdecoxib may decrease the antihypertensive activities of Acebutolol.	Investigational, Withdrawn
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Acebutolol.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Acebutolol.	Approved
Varenicline	The risk or severity of adverse effects can be increased when Acebutolol is combined with Varenicline.	Approved, Investigational
Venlafaxine	The serum concentration of Acebutolol can be increased when it is combined with Venlafaxine.	Approved
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Acebutolol.	Approved
Vilanterol	Acebutolol may decrease the bronchodilatory activities of Vilanterol.	Approved
Vinblastine	The serum concentration of Acebutolol can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Acebutolol can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Acebutolol can be increased when it is combined with Vinorelbine.	Approved, Investigational
Vinpocetine	Acebutolol may increase the hypotensive activities of Vinpocetine.	Investigational
Xylometazoline	Xylometazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Acebutolol.	Approved, Vet Approved
Zaltoprofen	Zaltoprofen may decrease the antihypertensive activities of Acebutolol.	Approved
Zileuton	Zileuton may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of Acebutolol can be increased when it is combined with Zimelidine.	Withdrawn
Zomepirac	Zomepirac may decrease the antihypertensive activities of Acebutolol.	Withdrawn

Food Interactions

Take without regard to meals; absorption rate and maximal concentration are slightly reduced but the extent of absorption is not affected.

References

Synthesis Reference

US3857952

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15324
KEGG Drug	D02338
KEGG Compound	C06803
PubChem Compound	1978
PubChem Substance	46509113
ChemSpider	1901
BindingDB	25755
ChEBI	2379
ChEMBL	CHEMBL642
Therapeutic Targets Database	DAP000484
PharmGKB	PA448011
Drug Product Database	11162
RxList	http://www.rxlist.com/cgi/generic2/ace.htm
Drugs.com	http://www.drugs.com/cdi/acebutolol.html
PDRhealth	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/sec1396.shtml
Wikipedia	Acebutolol

ATC Codes

C07AB04 — Acebutolol

C07BB04 — Acebutolol and thiazides

AHFS Codes

24:24.00

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Treatment	Cardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases	1
3	Terminated	Treatment	Hemangiomas	1
4	Completed	Treatment	Healthy Volunteers	1
Not Available	Completed	Treatment	Arrythmias / Nonvalvular Atrial Fibrillation	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Alphapharm Party Ltd.
Amneal Pharmaceuticals
Bryant Ranch Prepack
Caremark LLC
Kaiser Foundation Hospital
Major Pharmaceuticals
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Patheon Inc.
Pharmaceutical Utilization Management Program VA Inc.
Physicians Total Care Inc.
Professional Co.
Promius Pharma

Dosage forms

Form	Route	Strength
Capsule	Oral	200 mg/1
Capsule	Oral	400 mg/1
Tablet	Oral	400 mg
Tablet	Oral	100 mg
Tablet	Oral	200 mg

Prices

Unit description	Cost	Unit
Acebutolol hcl powder	7.08USD	g
Sectral 400 mg capsule	4.48USD	capsule
Sectral 200 mg capsule	3.37USD	capsule
Acebutolol HCl 400 mg capsule	1.39USD	capsule
Acebutolol 400 mg capsule	1.34USD	capsule
Sectral 400 mg Tablet	1.11USD	tablet
Acebutolol HCl 200 mg capsule	1.05USD	capsule
Acebutolol 200 mg capsule	1.01USD	capsule
Sectral 200 mg Tablet	0.56USD	tablet
Acebutolol 400 mg Tablet	0.51USD	tablet
Apo-Acebutolol 400 mg Tablet	0.51USD	tablet
Mylan-Acebutolol (Type S) 400 mg Tablet	0.51USD	tablet
Mylan-Acebutolol 400 mg Tablet	0.51USD	tablet
Novo-Acebutolol 400 mg Tablet	0.51USD	tablet
Nu-Acebutolol 400 mg Tablet	0.51USD	tablet
Rhotral 400 mg Tablet	0.51USD	tablet
Sectral 100 mg Tablet	0.37USD	tablet
Acebutolol 200 mg Tablet	0.26USD	tablet
Apo-Acebutolol 200 mg Tablet	0.26USD	tablet
Mylan-Acebutolol (Type S) 200 mg Tablet	0.26USD	tablet
Mylan-Acebutolol 200 mg Tablet	0.26USD	tablet
Novo-Acebutolol 200 mg Tablet	0.26USD	tablet
Nu-Acebutolol 200 mg Tablet	0.26USD	tablet
Rhotral 200 mg Tablet	0.26USD	tablet
Acebutolol 100 mg Tablet	0.17USD	tablet
Apo-Acebutolol 100 mg Tablet	0.17USD	tablet
Mylan-Acebutolol (Type S) 100 mg Tablet	0.17USD	tablet
Mylan-Acebutolol 100 mg Tablet	0.17USD	tablet
Novo-Acebutolol 100 mg Tablet	0.17USD	tablet
Nu-Acebutolol 100 mg Tablet	0.17USD	tablet
Rhotral 100 mg Tablet	0.17USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	136-138	Merck Index 13
water solubility	259 mg/L	Not Available
logP	1.71	HANSCH,C ET AL. (1995)
Caco2 permeability	-5.83	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.172 mg/mL	ALOGPS
logP	1.43	ALOGPS
logP	1.53	ChemAxon
logS	-3.3	ALOGPS
pKa (Strongest Acidic)	13.91	ChemAxon
pKa (Strongest Basic)	9.57	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	87.66 Å²	ChemAxon
Rotatable Bond Count	10	ChemAxon
Refractivity	94.87 m³·mol^-1	ChemAxon
Polarizability	38.51 Å³	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9156
Blood Brain Barrier	-	0.9659
Caco-2 permeable	-	0.8957
P-glycoprotein substrate	Substrate	0.7378
P-glycoprotein inhibitor I	Non-inhibitor	0.8557
P-glycoprotein inhibitor II	Non-inhibitor	0.8664
Renal organic cation transporter	Non-inhibitor	0.9466
CYP450 2C9 substrate	Non-substrate	0.8102
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Non-substrate	0.5752
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.8721
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9639
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.849
Biodegradation	Not ready biodegradable	0.8538
Rat acute toxicity	2.0487 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9821
hERG inhibition (predictor II)	Non-inhibitor	0.8555

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organic oxygen compounds

Sub Class

Organooxygen compounds

Direct Parent

Alkyl-phenylketones

Alternative Parents

Acetophenones / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Propargyl-type 1,3-dipolar organic compounds / Dialkylamines

Substituents

Alkyl-phenylketone / Acetophenone / Benzoyl / Phenol ether / Aryl alkyl ketone / Phenoxy compound / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid / 1,2-aminoalcohol

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

monocarboxylic acid amide, secondary amino compound, ether, aromatic amide, ethanolamines, propanolamine (CHEBI:2379 )

Targets

Details

1. Beta-1 adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: partial agonist

General Function:: Receptor signaling protein activity
Specific Function:: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:: ADRB1
Uniprot ID:: P08588
Uniprot Name:: Beta-1 adrenergic receptor
Molecular Weight:: 51322.1 Da

References

van den Meiracker AH, Man in 't Veld AJ, Fischberg DJ, Molinoff PB, van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA: Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density. J Cardiovasc Pharmacol. 1988 Apr;11(4):413-23. [PubMed:2453744 ]
Abrahamsson T: Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70. Eur J Pharmacol. 1989 May 2;164(1):121-8. [PubMed:2568935 ]
Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Beta-2 adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: partial agonist

General Function:: Protein homodimerization activity
Specific Function:: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:: ADRB2
Uniprot ID:: P07550
Uniprot Name:: Beta-2 adrenergic receptor
Molecular Weight:: 46458.32 Da

References

Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148 ]
Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]
Lima JJ: Relationship between beta adrenoceptor occupancy and receptor down-regulation induced by beta antagonists with intrinsic sympathomimetic activity. J Recept Signal Transduct Res. 1996 Sep-Nov;16(5-6):357-72. [PubMed:8968966 ]

Enzymes

Details

1. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Uniprot Name:: Cytochrome P450 2D6
Molecular Weight:: 55768.94 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Details

1. Solute carrier family 22 member 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Secondary active organic cation transmembrane transporter activity
Specific Function:: Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:: SLC22A1
Uniprot ID:: O15245
Uniprot Name:: Solute carrier family 22 member 1
Molecular Weight:: 61153.345 Da

References

Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]

Details

2. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

References

Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513 ]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:57

Get DrugBank to go!

Structure for DB01193 (Acebutolol)

Targets

References

References

Enzymes

References

Transporters

References

References